May the truth be with you: lubiprostone as EP receptor agonist/ClC-2 internalizing "inhibitor".

作者信息

Akiba Yasutada, Kaunitz Jonathan D

出版信息

Dig Dis Sci. 2012 Nov;57(11):2740-2. doi: 10.1007/s10620-012-2410-2.

DOI:10.1007/s10620-012-2410-2

PMID:23001408

Abstract

摘要

相似文献

May the truth be with you: lubiprostone as EP receptor agonist/ClC-2 internalizing "inhibitor".

Dig Dis Sci. 2012 Nov;57(11):2740-2. doi: 10.1007/s10620-012-2410-2.

Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.

Dig Dis Sci. 2012 Nov;57(11):2826-45. doi: 10.1007/s10620-012-2352-8. Epub 2012 Aug 25.

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

Br J Pharmacol. 2008 May;154(1):126-35. doi: 10.1038/bjp.2008.84. Epub 2008 Mar 10.

Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.

Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G647-56. doi: 10.1152/ajpgi.00183.2006. Epub 2006 Oct 19.

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

Biochem Biophys Res Commun. 2012 Sep 28;426(3):374-9. doi: 10.1016/j.bbrc.2012.08.097. Epub 2012 Aug 29.

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.

Gastroenterology. 2009 Sep;137(3):976-85. doi: 10.1053/j.gastro.2009.05.037. Epub 2009 May 18.

Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.

J Pharmacol Exp Ther. 2014 Jun;349(3):470-9. doi: 10.1124/jpet.114.213991. Epub 2014 Apr 8.

Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.

J Pharmacol Exp Ther. 2010 Jul;334(1):333-40. doi: 10.1124/jpet.110.166116. Epub 2010 Apr 20.

Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.

Dig Dis Sci. 2011 Feb;56(2):330-8. doi: 10.1007/s10620-010-1515-8. Epub 2010 Dec 23.

Lubiprostone targets prostanoid EP₄ receptors in ovine airways.

Br J Pharmacol. 2011 Jan;162(2):508-20. doi: 10.1111/j.1476-5381.2010.01058.x.

引用本文的文献

Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway.

Am J Physiol Lung Cell Mol Physiol. 2022 Mar 1;322(3):L305-L314. doi: 10.1152/ajplung.00388.2021. Epub 2022 Jan 12.

Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action.

Cells. 2020 Jul 26;9(8):1781. doi: 10.3390/cells9081781.

Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.

Front Pharmacol. 2017 Jun 30;8:418. doi: 10.3389/fphar.2017.00418. eCollection 2017.

Lubiprostone in constipation: clinical evidence and place in therapy.

Ther Adv Chronic Dis. 2015 Mar;6(2):40-50. doi: 10.1177/2040622314567678.

本文引用的文献

Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.

Dig Dis Sci. 2012 Nov;57(11):2826-45. doi: 10.1007/s10620-012-2352-8. Epub 2012 Aug 25.

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.

Expert Opin Drug Saf. 2012 Sep;11(5):841-50. doi: 10.1517/14740338.2012.708732. Epub 2012 Jul 27.

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.

Aliment Pharmacol Ther. 2012 Mar;35(5):587-99. doi: 10.1111/j.1365-2036.2011.04983.x. Epub 2012 Jan 18.

Severe defects in absorptive ion transport in distal colons of mice that lack ClC-2 channels.

Gastroenterology. 2012 Feb;142(2):346-54. doi: 10.1053/j.gastro.2011.10.037. Epub 2011 Nov 10.

Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.

Ann Pharmacother. 2011 Sep;45(9):1061-6. doi: 10.1345/aph.1Q219. Epub 2011 Aug 18.

Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.

Dig Dis Sci. 2011 Sep;56(9):2639-45. doi: 10.1007/s10620-011-1801-0. Epub 2011 Jul 19.

Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.

Dig Dis Sci. 2011 Feb;56(2):330-8. doi: 10.1007/s10620-010-1515-8. Epub 2010 Dec 23.

Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.

Dig Dis Sci. 2011 Feb;56(2):339-51. doi: 10.1007/s10620-010-1495-8. Epub 2010 Dec 8.

Lubiprostone targets prostanoid EP₄ receptors in ovine airways.

Br J Pharmacol. 2011 Jan;162(2):508-20. doi: 10.1111/j.1476-5381.2010.01058.x.

Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

BMC Gastroenterol. 2010 Sep 15;10:107. doi: 10.1186/1471-230X-10-107.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

May the truth be with you: lubiprostone as EP receptor agonist/ClC-2 internalizing "inhibitor".

Dig Dis Sci. 2012 Nov;57(11):2740-2. doi: 10.1007/s10620-012-2410-2.

Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.

Dig Dis Sci. 2012 Nov;57(11):2826-45. doi: 10.1007/s10620-012-2352-8. Epub 2012 Aug 25.

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

Br J Pharmacol. 2008 May;154(1):126-35. doi: 10.1038/bjp.2008.84. Epub 2008 Mar 10.

Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.

Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G647-56. doi: 10.1152/ajpgi.00183.2006. Epub 2006 Oct 19.

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

Biochem Biophys Res Commun. 2012 Sep 28;426(3):374-9. doi: 10.1016/j.bbrc.2012.08.097. Epub 2012 Aug 29.

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.

Gastroenterology. 2009 Sep;137(3):976-85. doi: 10.1053/j.gastro.2009.05.037. Epub 2009 May 18.

Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.

J Pharmacol Exp Ther. 2010 Jul;334(1):333-40. doi: 10.1124/jpet.110.166116. Epub 2010 Apr 20.

Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.

Dig Dis Sci. 2011 Feb;56(2):330-8. doi: 10.1007/s10620-010-1515-8. Epub 2010 Dec 23.

Lubiprostone targets prostanoid EP₄ receptors in ovine airways.

Br J Pharmacol. 2011 Jan;162(2):508-20. doi: 10.1111/j.1476-5381.2010.01058.x.

Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway.

Am J Physiol Lung Cell Mol Physiol. 2022 Mar 1;322(3):L305-L314. doi: 10.1152/ajplung.00388.2021. Epub 2022 Jan 12.

Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.

Front Pharmacol. 2017 Jun 30;8:418. doi: 10.3389/fphar.2017.00418. eCollection 2017.

Lubiprostone in constipation: clinical evidence and place in therapy.

Ther Adv Chronic Dis. 2015 Mar;6(2):40-50. doi: 10.1177/2040622314567678.

Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility.

Dig Dis Sci. 2012 Nov;57(11):2826-45. doi: 10.1007/s10620-012-2352-8. Epub 2012 Aug 25.

Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.

Expert Opin Drug Saf. 2012 Sep;11(5):841-50. doi: 10.1517/14740338.2012.708732. Epub 2012 Jul 27.

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.

Aliment Pharmacol Ther. 2012 Mar;35(5):587-99. doi: 10.1111/j.1365-2036.2011.04983.x. Epub 2012 Jan 18.

Severe defects in absorptive ion transport in distal colons of mice that lack ClC-2 channels.

Gastroenterology. 2012 Feb;142(2):346-54. doi: 10.1053/j.gastro.2011.10.037. Epub 2011 Nov 10.

Lubiprostone for constipation in adults with cystic fibrosis: a pilot study.

Ann Pharmacother. 2011 Sep;45(9):1061-6. doi: 10.1345/aph.1Q219. Epub 2011 Aug 18.

Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine.

Dig Dis Sci. 2011 Feb;56(2):330-8. doi: 10.1007/s10620-010-1515-8. Epub 2010 Dec 23.

Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84.

Dig Dis Sci. 2011 Feb;56(2):339-51. doi: 10.1007/s10620-010-1495-8. Epub 2010 Dec 8.

Lubiprostone targets prostanoid EP₄ receptors in ovine airways.

Br J Pharmacol. 2011 Jan;162(2):508-20. doi: 10.1111/j.1476-5381.2010.01058.x.

Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

BMC Gastroenterol. 2010 Sep 15;10:107. doi: 10.1186/1471-230X-10-107.